New perspectives on respiratory syncytial virus surveillance at the national level: lessons from the COVID-19 pandemic

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 754 KB, PDF-dokument

  • Anne C. Teirlinck
  • Caroline K. Johannesen
  • Eeva K. Broberg
  • Pasi Penttinen
  • Harry Campbell
  • Harish Nair
  • Rachel M. Reeves
  • Håkon Bøås
  • Mia Brytting
  • Wei Cai
  • Anna Sara Carnahan
  • Jean Sebastien Casalegno
  • Kostas Danis
  • Cillian De Gascun
  • Joanna Ellis
  • Hanne Dorthe Emborg
  • Manuel Gijon
  • Raquel Guiomar
  • Siddhivinayak S. Hirve
  • Helena Jiřincová
  • Hanna Nohynek
  • Jesus Angel Oliva
  • Richard Osei-Yeboah
  • John Paget
  • Gatis Pakarna
  • Richard Pebody
  • Lance Presser
  • Marie Rapp
  • Janine Reiche
  • Ana Paula Rodrigues
  • Elina Seppälä
  • Maja Socan
  • Karol Szymanski
  • Ramona Trebbien
  • Jaromíra Večeřová
  • Sylvie van der Werf
  • Maria Zambon
  • Adam Meijer
The emergence of SARS-CoV-2 and the resulting coronavirus disease 2019 (COVID-19) pandemic has led to the reconsideration of surveillance strategies for respiratory syncytial virus (RSV) and other respiratory viruses. The COVID-19 pandemic and the non-pharmaceutical interventions for COVID-19 had a substantial impact on RSV transmission in many countries, with close to no transmission detected during parts of the usual season of 2020–2021. Subsequent relaxation of social restrictions has resulted in unusual out-of-season resurgences of RSV in several countries, causing a higher healthcare burden and often a higher proportion of hospitalisations than usual among children older than 1 year in age [1]. In case of an emerging infectious disease with pandemic potential, preparedness to scale up surveillance for the emerging disease while continuing the maintenance of surveillance activities of pre-existing seasonal diseases is necessary. The COVID-19 pandemic demonstrated, however, a lack of surge capacity in respiratory surveillance [2]. Many of the existing respiratory surveillance systems across Europe were affected by the COVID-19 pandemic. Usual healthcare seeking routes, that are often the source of the sentinel surveillance, were altered for patients with respiratory symptoms to be diagnosed elsewhere for SARS-CoV-2 in many countries. Additionally, there were initially major reductions in testing availability, workforce numbers and access to test consumables due to repurposing of human and material resources to SARS-CoV-2 diagnostics and surveillance in the first half of 2020 [3, 4]. To help countries prioritise efforts towards construction of resilient and sustainable surveillance systems, the World Health Organization (WHO) European region and European Centre for Disease Prevention and Control (ECDC) convened Member State consultations to develop a strategic surveillance framework for a broader respiratory pathogen surveillance in the post-acute phase of the COVID-19 pandemic [5, 6]. It is important for RSV surveillance to be aligned and integrated within this broad respiratory surveillance framework for increased efficiency and sustainability of RSV surveillance. We here address the specific needs of RSV surveillance, based on the set of recommendations we proposed in 2019 [7], which we revised during a virtual workshop in October 2021, with 40 participants from 16 EU/EEA countries, representing expertise within RSV epidemiology, virology and public health. We take into consideration the need for robust surveillance of RSV to inform healthcare planning and appropriate timing of RSV prophylaxis and other preventive measures, and the lessons learned from the COVID-19 pandemic
OriginalsprogEngelsk
Artikelnummer2201569
TidsskriftEuropean Respiratory Journal
Vol/bind61
Udgave nummer4
Antal sider7
ISSN0903-1936
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
Conflict of interest: The content of the workshop on RSV surveillance was organised by SSI, RIVM and ECDC. This workshop was organised as an element of the Respiratory Syncytial Virus Consortium in Europe (RESCEU). RESCEU has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement 116019. This Joint Undertaking receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations. This workshop was only attended by publicly funded participants of academic and public health bodies. No industrial partners participated in the meeting or were involved in writing this manuscript. The institutions of the following co-authors are partners in RESCEU: National Institute for Public Health and the Environment, RIVM, the Netherlands (A.C. Teirlinck, A. Meijer, L. Presser); Statens Serum Institute, SSI, Denmark (T.K. Fischer, R. Trebbien, H-D. Emborg and C.K. Johannesen); University of Edinburgh (H. Nair, H. Campbell, R. Osei-Yeboah); PENTA (M. Gijjon). The institutions of the following co-authors are affiliated partners in RESCEU: Norwegian Institute of Public Health (H. Bøås, E. Seppälä); Nivel, the Netherlands ( J. Paget), Finnish Institute for Health and Welfare THL (H. Nohynek). E.K. Broberg and P. Penttinen (both ECDC) are members of the Scientific Advisory Group of RESCEU. H. Nohynek reports grants from GSK, Sanofi-Pasteur and Pfizer (to their institute THL, not their unit), outside the submitted work; and membership of the ESWI Scientific Committee. In addition, H. Nohynek has participated on data safety monitoring boards related to COVID-19 and Pertussis vaccines. J. Paget reports unrestricted research grants from Sanofi Pasteur, WHO, and Foundation for Influenza Epidemiology to Nivel, outside the submitted work. A.P. Rodrigues reports grants from AstraZeneca and Sanofi-Pasteur, and travel support from AstraZeneca, outside the submitted work. H. Nair reports grants from IMI, NIHR, WHO and Pfizer, consulting fees from BMGF, honoraria from AstraZeneca (all to their institute) and participated in DSM boards/advisory boards for Sanofi, ReViral, Novavax and GSK outside the submitted work. H. Campbell reports grants from EU IMI to the University of Edinburgh during the conduct of the study. H. Campbell also reports grants, consulting fees and travel support from WHO, BMGF and Sanofi (all paid via the University of Edinburgh). R.M. Reeves reports employment by IQVIA Real-World Solutions, and honoraria for manuscript writing from Sanofi Pasteur, both outside the submitted work. S. van der Werf reports a grant from Sanofi Pasteur, patents and participation in data safety monitoring boards and advisory boards, all outside the submitted work. C. De Gascun reports lecture honoraria from Sanofi-Aventis Ireland Limited, outside the submitted work. All other authors report no conflicts of interest outside the submitted work.

Publisher Copyright:
Copyright © The authors 2023.

ID: 360031282